1-3 of 3
Hyang-Min Byun, PhD
Close
Sort by
Journal Articles

A Phase I Biological Study of Azacitidine (Vidaza) to Determine the Optimal Biological Dose and Route of Administration.

Ilan Bernstein, MD, Hyang-Min Byun, PhD, Ann Mohrbacher, MD, Dan Douer, MD, Gerry Gorospe, III, RN, BSN, MSN, Allen S. Yang, MD, PhD, Casey L O'Connell, MD
Journal: Blood
Blood (2009) 114 (22): 1753.
https://doi.org/10.1182/blood.V114.22.1753.1753
Published: 2009
Journal Articles

Genome-Wide DNA Methylation Analysis of Patients with Myelodysplastic Syndrome After Azacitidine Treatment.

Hyang-Min Byun, PhD, Timothy Triche, Jr., M.S., Hyeoung-Joon Kim, MD, PhD, Hee Nam Kim, PhD, Yeo-Kyeoung Kim, MD, Il-Kwon Lee, Ph.D., Jae-Sook Ahn, MD, Je-Jung Lee, MD, Deok-Hwan Yang, MD, Hoon Kook, MD, Tai Ju Hwang, MD, Peter W. Laird, PhD, Daniel Weisenberger, Ph.D., Allen S. Yang, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 600.
https://doi.org/10.1182/blood.V114.22.600.600
Published: 2009
Journal Articles

Methylation Profiling of Three Homogenous Cancers: Chronic Myelogenous Leukemia (CML), Acute Promyelocytic Leukemia (APL) and Gastrointestinal Stromal Tumors (GIST).

Hyang-Min Byun, PhD, Shahrooz Eshaghian, MD, Jia Yi Jiang, MD, Si Ho Choi, MS, Laleh Ramezani, BSC, Dan Douer, MD, Guillermo Garcia-Manero, MD, Jean-Pierre Issa, MD, Dan Yang, MD, Ph.D, Jonathen Trent, MD, Ph.D, Allen S. Yang, MD, Ph.D
Journal: Blood
Blood (2006) 108 (11): 736.
https://doi.org/10.1182/blood.V108.11.736.736
Published: 2006